Anti-surrogate light chain antibodies

Inventor: Lawrence Horowitz (Mountain View, CA)

Assignee: I2 PHARMACEUTICALS, INC.

C07K16/42 C07K16/18 G01N33/564 C07K2317/33 C07K2317/92 C07K2317/94 G01N2800/102

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,858,448
App. No.: 15/548,274
Granted: Dec 8, 2020
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention concerns anti-surrogate light chain antibodies and their uses. In particular, the present invention concerns anti-VpreB1 antibodies and their uses.

Claims (38)

1. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a surrogate light chain (SLC) protein, wherein the SLC protein comprises a VpreB1 subunit, and wherein the VpreB1 subunit comprises an amino acid sequence of SEQ ID NO: 1, comprising:

(a) a light chain variable region sequence of SEQ ID NO: 36 and a heavy chain variable region sequence of SEQ ID NO: 52;

(b) a light chain variable region sequence of SEQ ID NO: 37 and a heavy chain variable region sequence of SEQ ID NO: 53;

(d) a light chain variable region sequence of SEQ ID NO: 39 and a heavy chain variable region sequence of SEQ ID NO: 55;

(e) a light chain variable region sequence of SEQ ID NO: 40 and a heavy chain variable region sequence of SEQ ID NO: 56;

(f) a light chain variable region sequence of SEQ ID NO: 41 and a heavy chain variable region sequence of SEQ ID NO: 57;

(g) a light chain variable region sequence of SEQ ID NO: 42 and a heavy chain variable region sequence of SEQ ID NO: 58;

(h) a light chain variable region sequence of SEQ ID NO: 43 and a heavy chain variable region sequence of SEQ ID NO: 59;

(i) a light chain variable region sequence of SEQ ID NO: 44 and a heavy chain variable region sequence of SEQ ID NO: 60;

(j) a light chain variable region sequence of SEQ ID NO: 45 and a heavy chain variable region sequence of SEQ ID NO: 61;

(k) a light chain variable region sequence of SEQ ID NO: 46 and a heavy chain variable region sequence of SEQ ID NO: 62;

(l) a light chain variable region sequence of SEQ ID NO: 47 and a heavy chain variable region sequence of SEQ ID NO: 63;

(m) a light chain variable region sequence of SEQ ID NO: 48 and a heavy chain variable region sequence of SEQ ID NO: 64;

(n) a light chain variable region sequence of SEQ ID NO: 49 and a heavy chain variable region sequence of SEQ ID NO: 65;

(o) a light chain variable region sequence of SEQ ID NO: 50 and a heavy chain variable region sequence of SEQ ID NO: 66; or

(p) a light chain variable region sequence of SEQ ID NO: 51 and a heavy chain variable region sequence of SEQ ID NO: 67.

2. The antibody of claim 1 , wherein said antigen-binding fragment is selected from the group consisting of Fab, Fab′, F(ab′) 2 , scFv, and (scFv) 2 fragments.

3. The antibody of claim 1 , wherein the SLC protein further comprises a λ5 subunit.

4. The antibody of claim 3 , wherein the λ5 subunit is a human λ5 protein comprising an amino acid sequence of SEQ ID NO: 7.

5. The antibody of claim 4 , wherein the λ5 subunit is a human λ5 dTail protein comprising SEQ ID NO: 9.

6. A composition comprising an isolated antibody, or antigen-binding fragment thereof, that specifically binds to a surrogate light chain (SLC) protein, wherein the SLC protein comprises a VpreB1 subunit, and wherein the VpreB1 subunit comprises an amino acid sequence of SEQ ID NO: 1, and wherein the antibody, or antigen-binding fragment thereof comprises: